Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Alessio CortelliniSebastiano ButiDaniele SantiniFabiana PerroneRaffaele GiustiMarcello TiseoMelissa BersanelliMaria MichiaraAntonino GrassadoniaDavide BroccoNicola TinariMichele De TursiFederica ZorattoEnzo VeltriRiccardo MarconciniFrancesco MalorgioCarlo GarufiMarco RussanoCecilia AnesiTea ZeppolaMarco FilettiPaolo MarchettiAndrea BotticelliGian Carlo Antonini CappelliniFederica De GalitiisMaria Giuseppa VitaleRoberto SabbatiniSergio BracardaRossana BerardiSilvia RinaldiMarianna TudiniRosa Rita SilvaAnnagrazia PiredduFrancesco AtzoriRita ChiariBiagio RicciutiDaniela IaconoMaria Rita MigliorinoAntonio RossiGiampiero PorzioKatia CannitaValeria CiciarelliMaria Concetta FargnoliPaolo Antonio AsciertoCorrado FicorellaPublished in: The oncologist (2019)
Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors but are frequent in clinical practice. This study quantifies the increased risk of developing immune-related adverse events (irAEs) in patients with pre-existing AIDs who had to be treated with anti-programmed death-1 immunotherapy. Nevertheless, their toxicities are mild and the incidence of grade 3/4 irAEs is not significantly higher compared with those of controls. These results will help clinicians in everyday practice, improving their ability to offer a proper counselling to patients, in order to offer an immunotherapy treatment even to patients with pre-existing autoimmune disease.